Michael Gunnar Knell Sells 6,645 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CAO Michael Gunnar Knell sold 6,645 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total value of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $8.85 during midday trading on Monday, reaching $276.34. 1,025,309 shares of the stock were exchanged, compared to its average volume of 924,952. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a market cap of $13.19 billion, a price-to-earnings ratio of -56.98, a PEG ratio of 2.77 and a beta of 1.38. The firm has a 50-day simple moving average of $214.85 and a two-hundred day simple moving average of $189.04. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $277.07.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same period in the previous year, the business posted $3.12 EPS. The business’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CRL shares. Mizuho set a $264.00 target price on shares of Charles River Laboratories International in a research note on Monday. Barclays reiterated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $42,000. Sfam LLC purchased a new position in Charles River Laboratories International in the 4th quarter valued at $43,000. Activest Wealth Management boosted its stake in Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth $46,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.